Quincy Medical Group Participates in COVID-19 Clinical Studies

Quin­cy Med­ical Group (QMG) is part­ner­ing with two dif­fer­ent research affil­i­at­ed com­pa­nies to sup­port the ongo­ing research efforts toward the advance­ment of test­ing for COVID-19 and a vac­cine to pre­vent the virus.

The two clin­i­cal research stud­ies QMG is cur­rent­ly par­tic­i­pat­ing in include:

• Abbott Mol­e­c­u­lar Inc.: The Abbott Real­Time SARS-CoV­‑2 Study is eval­u­at­ing the cur­rent stan­dard of care for nasopha­ryn­geal swab test­ing in an effort to devel­op a new, more sen­si­tive assay test for the COVID-19 virus. Poten­tial study par­tic­i­pants must have at least two symp­toms rec­og­nized by the Cen­ters for Dis­ease Con­trol and Pre­ven­tion (CDC) as pre­sent­ing signs or symp­toms of the COVID-19 virus, and be will­ing to pro­vide an addi­tion­al nasopha­ryn­geal swab when they arrive at QMG’s COVID test­ing site. Study par­tic­i­pants will be com­pen­sat­ed for their con­tri­bu­tions and par­tic­i­pa­tion at the time of sam­ple collection.

• AstraZeneca: The AZD7442 Study is eval­u­at­ing a new mon­o­clon­al anti­body com­bi­na­tion vac­cine for high-risk patients. Poten­tial study par­tic­i­pants eli­gi­ble for the study include patients at least 60 years of age, and per­sons at increased risk of infec­tion, due to close-prox­im­i­ty living/​working envi­ron­ments such as long-term care facil­i­ties and nurs­ing homes. Poten­tial par­tic­i­pants must be able to come to the QMG test­ing site in order to par­tic­i­pate in the study.

“Clin­i­cal research is impor­tant in advanc­ing test­ing and pre­ven­tion mea­sures for COVID-19,” said QMG Chief Clin­i­cal Offi­cer Shau­na Har­ri­son. ​“QMG is hon­ored to par­tic­i­pate in and offer these clin­i­cal stud­ies local­ly to help fur­ther research sur­round­ing COVID-19.”

For more infor­ma­tion on these stud­ies, vis­it clin​i​cal​tri​als​.gov or call 217−277−4070, ext. 5580 or 5581, to speak to the Clin­i­cal Research Department.